Early‐Onset Colorectal Cancer With Liver‐Only Metastases: A Retrospective Cohort Study Integrating Prospectively Collected Real‐World Clinical and Molecular Data From an Australian National Database (2009–2024) to Guide Treatment Planning
Medical Journal of Australia · 2026
DOI: 10.5694/mja2.70266 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Medical Journal of Australia, 2026. Verfasst von Savio G Barreto und 20 weiteren Autor:innen. Beteiligte Einrichtung: Flinders Medical Centre, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Liver Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To leverage the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) registry (an Australian cancer database) to explore the ideal timing and sequence of therapies and the factors influencing these decisions in colorectal cancer (CRC) patients with liver‐only metastases to inform contemporary decision‐making and future trials. Study Type Retrospective registry‐based cohort study using the TRACC registry. Setting and Participants Consecutive patients with liver‐only metastatic CRC enrolled in the TRACC registry. Main Outcome Measures To explore cancer biology, intended treatment at presentation, actual treatment received and the resultant outcomes for early‐onset CRC (EOCRC) (≤ 50 years) and late‐onset CRC (LOCRC) (> 50 years) patients with liver‐only metastases from a real‐world perspective.
Results
Between 14 January 2009 and 2 September 2024, 1691 patients with liver‐only metastatic CRC were enrolled in TRACC. These included 276 EOCRC patients (16.3%) and 1415 LOCRC patients (83.7%). In the EOCRC subset, there were more females (48.2% vs. 34.5%, p < 0.001), less comorbidity (Charlson comorbidity index score 0, 90% vs. 59%, p < 0.001), more left‐sided primaries (76.1% vs. 65.7%, p < 0.001), more synchronous disease (53.3% vs. 42.1%, p < 0.001) and BRAF V600E mutations (13.9% vs. 8.1%; p = 0.010). Overall, EOCRC patients had a longer median survival compared with LOCRC patients (3.20 vs. 2.38 years, p < 0.001). For the 662 patients (39.1%) undergoing liver resection, median survival was 5.99 years in EOCRC patients and 5.88 years in LOCRC patients. For all patients and for those undergoing resection, respectively, B‐Raf proto‐oncogene, serine/threonine kinase ( BRAF ) (hazard ratio, 1.97 [ p < 0.001] and hazard ratio, 2.25 [ p < 0.001]) and Kirsten rat sarcoma viral oncogene homologue ( KRAS ) mutations were associated with worse outcomes (hazard ratio, 1.29 [ p < 0.001] and hazard ratio, 1.34 [ p = 0.003]).
Conclusion
Differences in sex distribution, BRAF mutation rates, primary tumour site and overall survival suggest biological differences between EOCRC and LOCRC. Liver resection was associated with improved survival in LOCRC, with the benefits of all therapies varying depending on age, primary tumour site and whether patients presented with synchronous or metachronous liver‐only metastases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Flinders Medical Centre, Adelaide, South Australia, Australia.
- Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia, Australia.
- Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Adelaide, South Australia, Australia.
- Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
- Gold Coast University Hospital, Gold Coast, Queensland, Australia.
- Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
ORCID-Profile: Savio G Barreto
Zitieren
APA
Barreto, S. G., Karapetis, C. S., Ullah, S., Burge, M., Caird, S., Campbell, A., Jalali, A., Jennens, R., Khattak, M. A., Lee, B., Lim, S. H., Mendis, S., Nott, L., Price, T. J., Shapiro, J. D., Tie, J., Torres, J., Williams, C., Wong, R., …, & Gibbs, P. (2026). Early‐Onset Colorectal Cancer With Liver‐Only Metastases: A Retrospective Cohort Study Integrating Prospectively Collected Real‐World Clinical and Molecular Data From an Australian National Database (2009–2024) to Guide Treatment Planning. Medical Journal of Australia. https://doi.org/10.5694/mja2.70266
Vancouver
Barreto SG, Karapetis CS, Ullah S, Burge M, Caird S, Campbell A, et al. Early‐Onset Colorectal Cancer With Liver‐Only Metastases: A Retrospective Cohort Study Integrating Prospectively Collected Real‐World Clinical and Molecular Data From an Australian National Database (2009–2024) to Guide Treatment Planning. Medical Journal of Australia. 2026. doi:10.5694/mja2.70266
BibTeX
@article{Barreto2026,
author = {Barreto, Savio G and Karapetis, Christos S and Ullah, Shahid and Burge, Matthew and Caird, Susan and Campbell, Angus and Jalali, Azim and Jennens, Ross and Khattak, Muhammad A and Lee, Belinda and Lim, Stephanie H and Mendis, Shehara and Nott, Louise and Price, Timothy J and Shapiro, Jeremy D and Tie, Jeanne and Torres, Javier and Williams, Colin and Wong, Rachel and Wong, Vanessa and Gibbs, Peter},
title = {Early‐Onset Colorectal Cancer With Liver‐Only Metastases: A Retrospective Cohort Study Integrating Prospectively Collected Real‐World Clinical and Molecular Data From an Australian National Database (2009–2024) to Guide Treatment Planning},
journal = {Medical Journal of Australia},
year = {2026},
doi = {10.5694/mja2.70266}
}
EUVIMED